Two cases of Alzheimer's disease showing deterioration of behavioral and psychological symptoms of dementia induced by switching from rivastigmine to donepezil

Neuropsychiatric Disease and Treatment

Volumn 9, Issue 1, 2012, Pages 49-53

  Kimura, Takemi ^a   Takamatsu, Junichi ^a  

^a Kikuchi National Hospital Division of Clinical Research   (Japan)

Author keywords

Alzheimer's disease; Behavioral and psychological symptoms of dementia; Cholinesterase inhibitors; Donepezil; Japanese; Neuropsychiatric inventory; Rivastigmine; Switching

Indexed keywords

CHOLINESTERASE; CHOLINESTERASE INHIBITOR; DONEPEZIL; HERBACEOUS AGENT; PLACEBO; RIVASTIGMINE; TANDOSPIRONE; UNCLASSIFIED DRUG; YOKUKANSAN;

ADULT; AGED; AGGRESSIVENESS; AGITATION; ALZHEIMER DISEASE; ARTICLE; BLOOD EXAMINATION; BRAIN BLOOD FLOW; BRAIN CORTEX; CASE REPORT; CINGULATE GYRUS; CLINICAL EXAMINATION; COGNITIVE DEFECT; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEMENTIA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME INHIBITION; FEMALE; HERBAL MEDICINE; HUMAN; INSOMNIA; IRRITABILITY; JAPAN; MENTAL DETERIORATION; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARALLEL DESIGN; RANDOMIZED CONTROLLED TRIAL; SCINTIGRAPHY; SIDE EFFECT; TREATMENT RESPONSE; URINALYSIS; WHITE MATTER;

EID: 84872093546     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S37688     Document Type: Article

References (16)

1. Villarroya M, Garcia AG, Marco JL. New classes of AChE inhibitors with additional pharmacological effects of interest for the treatment of Alzheimer's disease. Curr Pharm Des. 2004;10(25):3177-3184.
2. Akaike A, Kume T. Neurodegenerative disease and nicotinic receptor. J Clin Exp Med. 2004;210(7-8):687-690. Japanese.
3. Nakamura Y, Imai Y, Shigeta M, et al. A 24-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of the rivastigmine patch in Japanese patients with Alzheimer's disease. Dement Geriatr Cogn Dis Extra. 2011;1(1): 163-179.
4. Weinstock M. Selectivity of cholinesterase inhibition: clinical implications for the treatment of Alzheimer's disease. CNS Drugs. 1999;12(4):307-323.
5. Bullock R, Touchon J, Bergman H, et al. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Curr Med Res Opin. 2005;21(8):1317-1327.
6. Bullock R, Bergman H, Touchon J, et al. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease. Curr Med Res Opin. 2006;22(3):483-494.
7. Blesa R, Bullock R, He Y, et al. Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease. Pharmacogenet Genomics. 2006;16(11):771-774.
8. Cumbo E. Differential effects of rivastigmine, galantamine and donepezil on behavioral and psychological symptoms in patients with Alzheimer's disease: 18-month, randomized, open-label trial. Prim Care Comm Psych. 2005;10(3):95-102.
9. Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurolog y. 2001;57(3):489-495.
10. Bouman W P, Pinner G. Violent behavior-associated with donepezil. Am J Psychiatry. 1998;155(11):1626-1627.
11. Bianchetti A, Trabucchi M, Cipriani G. Aggressive behaviour associated with donepezil treatment: a case report. Int J Geriatr Psychiatry. 2003;18(7):657-658.
12. Kimura T, Takamatsu J. Pilot study of pharmacological treatment for frontotemporal dementia: risk of donepezil treatment of behavioral and psychological symptoms. Geriatr Gerontol Int. In press 2013.
13. Kimura T, Hayashida H, Miyauchi D, Takamatsu J. Drug-resistant dementia with Lewy bodies: case report of 3 patients showing good response to aripiprazole treatment. Clin Psychiatry. 2010;52(6):575-582. Japanese.
14. Mercier F, Lefèvre G, Huang HL, Schmidli H, Amzal B, Appel-Dingemanse S. Rivastigmine exposure provided by a transdermal patch versus capsules. Curr Med Res Opin. 2007;23(12):3199-3204.
15. Panisset M, Roudier M, Saxton J, Boller F. Severe impairment battery. A neuropsychological test for severely demented patients. Arch Neurol. 1994;51(1):41-45.
16. Galasko D, Bennett D, Sano M, Marson D, Kaye J, Edland SD; Alzheimer's Disease Cooperative Study. ADCS Prevention Instrument Project: assessment of instrumental activities of daily living for community-dwelling elderly individuals in dementia prevention clinical trials. Alzheimer Dis Assoc Disord. 2006;20 Suppl 3:S152-S169.